New hope for liver disease: drug shows promise in reducing damage

NCT ID NCT06730061

Ongoing Disease control Sponsor: Ipsen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study tests a daily pill called elafibranor in about 18 Japanese adults with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants had not responded well to standard treatment. The main goal is to see if the drug improves key liver blood tests (ALP and bilirubin) over 52 weeks, with a possible extension up to 6 years. The study is active but not recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BILIARY CHOLANGITIS

Contacts and locations

Locations

Chugoku Rosai Hospital

Hiroshima, Japan
Fukushima Medical University Hospital

Fukushima, Japan
Hamamatsu University Hospital

Shizuoka, Japan
Juntendo University Hospital

Tokyo, Japan
Kagawa University Hospital

Kagawa, Japan
Kagoshima University Hospital

Kagoshima, Japan
Nagaoka Red Cross Hospital

Niigata, Japan
Nara Medical University Hospital

Nara, Japan
National Hospital Organization Nagasaki Medical Center

Nagasaki, Japan
National Hospital Organization Osaka National Hospital

Osaka, Japan
Niigata University Medical & Dental Hospital

Niigata, Japan
Nippon Medical School - Chiba Hokusoh Hospital

Chiba, Japan
Shinshu University Hospital

Nagano, Japan
Teikyo University Hospital

Tokyo, Japan
Teine Keijinkai Hospital

Hokkaido, Japan
Tokyo Metropolitan Komagome Hospital

Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.